Registration‐directed phase 1/2 trial of irinotecan for pediatric solid tumors-Reference-Cited by-同舟云学术

Registration‐directed phase 1/2 trial of irinotecan for pediatric solid tumors

Published:2019-05 Issue:5 Volume:61 Page:453-458
ISSN:1328-8067
Container-title:Pediatrics International
language:en
Short-container-title:Pediatrics International

Author:

Makimoto Atsushi¹²^ORCID,Mugishima Hideo³,Taga Takashi⁴,Ishida Yuji⁵,Nagatoshi Yoshihisa⁶,Ida Kohmei⁷,Kumagai Masaaki⁸,Kimura Toshimi⁹,Ohashi Yasuo¹⁰,Kaneko Michio¹¹

Affiliation:

1. Department of Pediatric Oncology National Cancer Center Hospital (affiliated until 2013)Tokyo Japan

2. Department of Hematology Oncology Tokyo Metropolitan Children's Medical Center Tokyo Japan

3. Department of Pediatrics Nihon University School of Medicine Tokyo Japan

4. Department of Pediatrics Shiga University of Medical Science Shiga Japan

5. Department of Pediatric Oncology Shizuoka Cancer Center Shizuoka Japan

6. Department of Pediatric Oncology National Kyushu Cancer Center Fukuoka Japan

7. Department of Pediatrics Teikyo University Mizonokuchi Hospital Kanagawa Japan

8. Department of Hematology/Oncology National Center for Child Health and Development Tokyo Japan

9. Department of Pharmacy Tokyo Women's Medical University Tokyo Japan

10. Department of Integrated Science and Engineering for Sustainable Society Chuo University Tokyo Japan

11. Department of Pediatric Surgery University of Tsukuba School of Medicine Ibaraki Japan

Funder

Ministry of Health, Labour and Welfare

Publisher

Wiley

Subject

Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ped.13826

Reference19 articles.

1. Direct Translation of a Protracted Irinotecan Schedule From a Xenograft Model to a Phase I Trial in Children

2. A Phase I Study of Irinotecan As a 3-Week Schedule in Children With Refractory or Recurrent Solid Tumors

3. Phase I Study of Irinotecan in Pediatric Patients With Malignant Solid Tumors

4. Phase II Trial of Irinotecan in Children With Refractory Solid Tumors: A Children's Oncology Group Study

5. A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: A European cooperation of the Société Française d’Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG)

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Irinotecan dosing and pharmacogenomics: a comprehensive exploration based on UGT1A1 variants and emerging insights;Journal of Chemotherapy;2024-05-06

2. Supramolecular assembly of isomeric SN-38 prodrugs regulated by conjugation sites;Journal of Materials Chemistry B;2024

3. Efficiency of Protective Interventions on Irinotecan-Induced Diarrhea: A Systematic Review and Meta-Analysis;Integrative Cancer Therapies;2024-01

4. Binding of combined irinotecan and epicatechin to a pH-responsive DNA tetrahedron for controlled release and enhanced cytotoxicity;Journal of Molecular Structure;2023-07

5. Effect of Bifidobacterium animalis subsp. lactis SF on enhancing the tumor suppression of irinotecan by regulating the intestinal flora;Pharmacological Research;2022-10